Daniel Kotlarz

Dr. Daniel Kotlarz is a Joint Helmholtz Young Investigator Group Leader at Helmholtz Munich, focusing on pediatric inflammatory bowel disease (IBD) and primary immunodeficiencies through a systems biology and multi-omics approach.

• Current Affiliation: Helmholtz Munich, Computational Health Center
• Previous Roles: Group Leader at Helmholtz Munich (2017–), Postdoctoral Fellow at Boston Children’s Hospital (2016–2014), Resident Physician at LMU Munich (2014–)

His research explores the genetic and immune mechanisms underlying pediatric IBD, including roles in NOD2 polymorphisms, NOX1 deficiency, and TGF-beta signaling. His work integrates cell death regulation, reactive oxygen species (ROS), and inflammatory pathways.

Recent publications highlight discoveries in RIPK1 deficiency, TGFB1 mutations, and IL-21 receptor defects, linking these to immunodeficiency and chronic inflammation. These studies emphasize translational genomics and therapeutic targeting of key signaling nodes.

Scientific Awards:

• Heinz Maier-Leibnitz Prize (2020)
• John Harries Prize (2019)
• Best Paper Prize (2019)
• Rolf Becker-Preis (2018)
• Rising Star scientist (2018)
• Innovation Prize (2015)
• Dr. Holger Müller Prize (2014)